Latest Articles

Publication Date
Inguinal endometriosis: a rare entity of a common condition .

A woman in her mid-40s experienced a painful lump in the right groin area for 5 years, with exacerbation during menstruation, coughing and sneezing. Initial treatment with depot methylprednisolone acetate …

Published: Sept. 11, 2025, midnight
Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial - Reproductive Health

Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial Reproductive Health

Published: March 9, 2025, 9:57 p.m.
Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial.

Published: March 9, 2025, midnight
Primary Low-Grade Endometrial Stromal Sarcoma of the Ovary Arising From Endometriosis: A Case Report.

Low-grade endometrial stromal sarcoma (LGESS) is a rare mesenchymal tumor of female genital tract malignancies. While it primarily arises in the uterus, extrauterine cases, including those originating in the ovary, …

Published: Feb. 23, 2025, midnight
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.

Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.

Published: Jan. 31, 2025, midnight
SAHPRA Issues Warning on Meningioma Risk with Medroxyprogesterone Acetate Use, Updates Product Information - Devdiscourse

SAHPRA Issues Warning on Meningioma Risk with Medroxyprogesterone Acetate Use, Updates Product Information Devdiscourse

Published: Jan. 17, 2025, 4:01 p.m.
Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data.

Medroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, like all pharmaceutical agents, MPA …

Published: Dec. 11, 2024, midnight
Cost-effectiveness of long-acting progestogens versus the combined oral contraceptives pill for preventing recurrence of endometriosis-related pain following surgery: an economic evaluation alongside the PRE-EMPT trial.

To evaluate the cost-effectiveness of long-acting progestogens (LAP), including levonorgestrel-releasing intrauterine system (LNG-IUS) and depot-medroxyprogesterone acetate (DMPA), compared with the combined oral contraceptives pill (COCP) in preventing recurrence of endometriosis-related …

Published: Dec. 9, 2024, midnight
Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT.

Endometriosis affects 1 in 10 women, many of whom have surgery for persistent pain. Recurrence of symptoms following an operation is common. Although hormonal treatment can reduce this risk, there …

Published: Oct. 13, 2024, 8:56 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!